Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 15/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.49 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4184616 | 0.91 | FASN (0.61) | FASN | |
| SCHEMBL4170791 | 0.90 | FASN (0.60) | FASN | |
| SCHEMBL4167169 | 0.89 | FASN (0.59) | FASN | |
| SCHEMBL4175298 | 0.89 | FASN (0.59) | FASNPARP10PARP14 | |
| SCHEMBL4169865 | 0.89 | FASN (0.59) | FASN | |
| SCHEMBL4179408 | 0.89 | FASN (0.59) | FASN | |
| SCHEMBL4182310 | 0.89 | FASN (0.58) | FASNPARP10PARP14NPC1RAB9A | |
| SCHEMBL4174590 | 0.89 | FASN (0.56) | FASN | |
| SCHEMBL4183758 | 0.89 | FASN (0.54) | FASNPARP10PARP14NPC1HSD11B1 | |
| SCHEMBL4172334 | 0.88 | FASN (0.58) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| WO-2008075070-A1 | SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | FABP4, GPR119, FASN | FASN 3/4885PARP10 810/4885PARP14 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.